IN2013MU02206A - - Google Patents

Info

Publication number
IN2013MU02206A
IN2013MU02206A IN2206MU2013A IN2013MU02206A IN 2013MU02206 A IN2013MU02206 A IN 2013MU02206A IN 2206MU2013 A IN2206MU2013 A IN 2206MU2013A IN 2013MU02206 A IN2013MU02206 A IN 2013MU02206A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
water
sycrest
saphris
asenapine
Prior art date
Application number
Other languages
English (en)
Inventor
Veerababu Ramabrahmmam Taduri
Viral Ramesh Vaidya
Jigar Rameshchandra Lalani
Original Assignee
Alembic Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Ltd filed Critical Alembic Pharmaceuticals Ltd
Priority to PCT/IB2014/062575 priority Critical patent/WO2014207664A2/en
Priority to IN2206MU2013 priority patent/IN2013MU02206A/en
Publication of IN2013MU02206A publication Critical patent/IN2013MU02206A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2206MU2013 2013-06-28 2014-06-25 IN2013MU02206A (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2014/062575 WO2014207664A2 (en) 2013-06-28 2014-06-25 Stable pharmaceutical composition of asenapine
IN2206MU2013 IN2013MU02206A (ko) 2013-06-28 2014-06-25

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2206MU2013 IN2013MU02206A (ko) 2013-06-28 2014-06-25

Publications (1)

Publication Number Publication Date
IN2013MU02206A true IN2013MU02206A (ko) 2015-06-12

Family

ID=52142775

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2206MU2013 IN2013MU02206A (ko) 2013-06-28 2014-06-25

Country Status (2)

Country Link
IN (1) IN2013MU02206A (ko)
WO (1) WO2014207664A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125152A2 (en) * 2014-02-18 2015-08-27 Hetero Research Foundation Pharmaceutical compositions of asenapine
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
MX2020014286A (es) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
CN109288800A (zh) * 2018-10-30 2019-02-01 天津仁生医药科技有限公司 马来酸阿塞那平片及其制备方法
CN109330984A (zh) * 2018-11-20 2019-02-15 天津仁生医药科技有限公司 一种马来酸阿塞那平舌下片及其制备方法
WO2021085211A1 (ja) * 2019-10-28 2021-05-06 久光製薬株式会社 アセナピン－ｎ－オキシドの生成を抑制する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL180465B1 (pl) * 1994-03-02 2001-02-28 Akzo Nobel Nv Kompozycja farmaceutyczna zawierajaca trans-5-chloro-2-metylo-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pirol PL PL PL
WO2012123325A1 (en) * 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID

Also Published As

Publication number Publication date
WO2014207664A3 (en) 2015-04-02
WO2014207664A2 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
IN2013MU02206A (ko)
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
PH12015500823A1 (en) Modified release formulations for oprozomib
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
CA2863376A1 (en) Gastroretentive tablets
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
WO2017098533A3 (en) Process for preparation of lisdexamphetamine
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
WO2017004172A8 (en) Total synthesis of shishijimicin a and analogs thereof
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
WO2017085733A3 (en) Analgesic lipoic acid derivatives and the preparation thereof